OncoMatch/Clinical Trials/NCT05048901
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Is NCT05048901 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Cabozantinib and Lanreotide for neuroendocrine tumors,gastroenteropancreatic.
Treatment: Cabozantinib · Lanreotide — This is an Open-Label Phase I/II Study of daily cabozantinib plus lanreotide every 4 w eeks to treat advanced G1-2 gastroentero-pancreatic neuroendocrine tumor (GEP-NET) patients who failed to one line or more than one line of small molecule kinase inhibitor or well-differentiated (W-D) G3 GEP-NET who failed to one line of small molecule kinase inhibitor or chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Disease stage
Required: Stage III, IV
Grade: G1G2well-differentiated G3
G1 or G2 NET of GEP origin with locally advanced or metastatic stage ... or W-D G3 NET of GEP origin with locally advanced or metastatic stage
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: small molecule kinase inhibitor
failed to one line or more than one line of small molecular kinase inhibitor (mTOR inhibitor or other targeted kinase inhibitor)
Must have received: chemotherapy
failed to one line or more than one line of chemotherapy or small molecule kinase inhibitor
Cannot have received: cabozantinib (cabozantinib)
Prior use of cabozantinib
Lab requirements
Blood counts
ANC ≥ 1500/µL without G-CSF support; WBC ≥ 2500/µL; platelets ≥ 100,000/µL without transfusion; hemoglobin ≥ 9 g/dL
Kidney function
serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min
Liver function
ALT, AST, ALP ≤ 3 x ULN; if liver metastasis, AST, ALT ≤ 5 x ULN; ALP ≤ 5 x ULN with documented bone metastases; total bilirubin ≤ 1.5 x ULN (≤ 3 x ULN for Gilbert's disease); serum albumin ≥ 2.8 g/dl; moderate to severe hepatic impairment (Child-Pugh B or C) excluded
Cardiac function
QTcF ≤ 500 ms; no NYHA Class 3 or 4 CHF, unstable angina, serious arrhythmias, recent (within 6 months) stroke, MI, or thromboembolic event
Adequate organ and marrow function ... see full laboratory criteria. Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms ... Cardiovascular disorders: Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias. Uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment. Stroke (including TIA), MI, or other ischemic event, or thromboembolic event (e.g., DVT, PE) within 6 months before first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05048901 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cabozantinib disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages